EGFR and non-small cell lung carcinoma: This was the case for the FLEX (First-Line ErbituX in lung cancer) study, which compared cisplatin and vinorelbine plus cetuximab with cisplatin and vinorelbine alone in the first-line treatment of 1125 patients with EGFR-expressing, advanced NSCLC.